Volume 21, Issue 3 pp. 358-370
Review Article
Open Access

Pharmacological Treatment for Atrial Fibrillation

Kaoru Sugi MD PhD

Kaoru Sugi MD PhD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Mahito Noro MD PhD

Mahito Noro MD PhD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Takao Sakata MD PhD

Takao Sakata MD PhD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Naoki Tezuka MD

Naoki Tezuka MD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Takeshi Nakae MD

Takeshi Nakae MD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Kenta Kumagai MD

Kenta Kumagai MD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Tsuyoshi Sakai MD PhD

Tsuyoshi Sakai MD PhD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Ayaka Numata MD PhD

Ayaka Numata MD PhD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Hidetoshi Itakura MD

Hidetoshi Itakura MD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Akiyoshi Moriyama MD

Akiyoshi Moriyama MD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
Shingo Kujime MD

Shingo Kujime MD

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center

Search for more papers by this author
First published: 23 August 2012

Abstract

Pharmacological treatment for atrial fibrillation has a variety of purposes, such as pharmacological defibrillation, maintenance of sinus rhythm, heart rate control to prevent congestive heart failure and prevention of both cerebral infarction and atrial remodeling. Sodium channel blockers are superior to potassium channel blockers for atrial defibrillation, while both sodium and potassium channel blockers are effective in the maintenance of sinus rhythm. In general, digitalis or Ca antagonists are used to control heart rate during atrial fibrillation to prevent congestive heart failure, while amiodarone or bepridil also reduce heart rates during atrial fibrillation. Anticoagulant therapy with warfarin is recommended to prevent cerebral infarction and angiotensin converting enzyme antagonists or angiotensin II receptor blockers are also used to prevent atrial remodeling. One should select appropriate drugs for treatment of atrial fibrillation according to the patient's condition.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.